ROPEGINTERFERON INJ,SOLN

Clinical Criteria Summary

Pregnancy testing
Estimated GFR (eGFR)
Liver enzyme / function tests
Screen for subclinical thyroid dysfunction, autoimmune disorders, and neuropsychiatric disorders.

Patients not on hydroxyurea: Initiate at 100 mcg SC every 2 weeks. Increase dose by 50 mcg every 2 weeks up to a maximum of 500 mcg until hematologic parameters are stabilized (hematocrit less than 45%, platelets less than 400 x 109/L, and leukocytes less than 10 x 109/L).
Patients transitioning from hydroxyurea: Initiate at 50 mcg SC every 2 weeks in combination with hydroxyurea. Increase ropegIFN by 50 mcg every 2 weeks up to a maximum of 500 mcg until hematologic stabilization. During Weeks 3–12, gradually taper off hydroxyurea by reducing the total biweekly dose by 20%–40% every 2 weeks. Discontinue hydroxyurea by Week 13.
Maintenance: Maintain the 2-week dosing interval for at least 1 year that achieved hematologic stability. Thereafter, extend to every 4 weeks.
Dose modifications due to adverse reactions: Refer to prescribing information.

Boxed Warning: Risk of serious disorders; may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Monitor closely and discontinue if persistently severe or worsen.
Contraindications: Severe psychiatric disorders (particularly severe depression, suicidal ideation, or suicide attempt), hypersensitivity to IFNs including IFN alfa-2b or inactive ingredients, moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment, history or presence of active serious/untreated autoimmune disease, immunosuppressed transplant recipients.
Other Warnings/Precautions: Depression and suicide; endocrine toxicity; cardiovascular toxicity; decreased peripheral blood counts; hypersensitivity reactions; pancreatitis; colitis; pulmonary toxicity; ophthalmologic toxicity; hyperlipidemia; hepatotoxicity; renal toxicity; dental and periodontal toxicity; dermatologic toxicity. Avoid driving and operating machinery.
Common Adverse Events (>40%): Influenza-like illness, arthralgia, fatigue, pruritus, nasopharyngitis, musculoskeletal pain.

CYP450 substrates with narrow therapeutic index: Monitor for adverse reactions; adjust dose of concomitant drug if needed.
Myelosuppressive agents: Avoid concomitant use. Monitor patients receiving concomitant myelosuppressives.
Narcotics, hypnotics, or sedatives: Monitor for excessive central nervous system toxicity.

Pregnancy: Can cause fetal harm. Advise effective contraception. May disrupt menstrual cycles. Generally avoid; use in pregnancy may be considered after weighing risks vs benefits on a case-by-case basis.
Lactation: Advise against breastfeeding during treatment and for 8 weeks after the final dose.
Renal Impairment: Avoid use if eGFR < 30 mL/min. No dosage adjustment necessary for eGFR ≥ 30 mL/min.
Hepatic Impairment: Contraindicated in Child-Pugh B or C hepatic impairment. Reduce dosage if increased liver enzymes are progressive and persistent.
Geriatric Use: Insufficient data to determine differences in response. Use cautious dosing.

NCCN Guidelines: Recommended as an alternative therapy for initial cytoreductive treatment in low-risk PV when potential indications are present (new thrombosis or disease-related major bleeding, frequent phlebotomy or intolerance to phlebotomy, splenomegaly, progressive thrombocytosis and/or leukocytosis, disease-related symptoms such as pruritus, night sweats, fatigue).
ELN Guidelines: Cytoreductive therapy is recommended for low-risk PV with poor tolerance to phlebotomy, symptomatic progressive splenomegaly (>5-cm increase in past year), or persistent leukocytosis (leukocyte count >20 x 109/L confirmed at 3 months). Should be considered for progressive leukocytosis, extreme thrombocytosis (>1500 x 109 platelets/L) with disease-related bleeding, or inadequate hematocrit control with phlebotomies. Can be considered for high symptom burden/severe itching not relieved by standard measures, or case-by-case for relevant cardiovascular risk despite primary prevention.
Age-based selection: Preferred in patients <60 years old; hydroxyurea is preferred in patients >60 years of age.
VHA Place in Therapy: May be used as a less preferred (higher-cost) alternative to pegIFN alfa-2a in patients with PV, including low-risk PV (<60 years without history of thrombosis) who are symptomatic and have potential indications for cytoreductive therapy. Both should generally be avoided in pregnant patients and patients of childbearing potential not on contraception.

Download CFU PDF